PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20081260-0	2009	Effect of diethyldithiocarbamate (DDC) and ticlopidine on CYP1A2 activity and caffeine metabolism: an in vitro comparative study with human cDNA-expressed CYP1A2 and liver microsomes.	Ticlopidine	43-54	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	58-64	
20081260-4	2009	A comparative in vitro study provides clear evidence that ticlopidine and DDC, applied at concentrations that inhibit the above-mentioned CYP isoforms, potently (as compared to furafylline) inhibit human CYP1A2 and caffeine metabolism, in particular 1-N- and 3-N-demethylation.	Ticlopidine	58-69	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	204-210	
10759690-7	2000	TCL was also a moderate inhibitor of CYP1A2 (Ki = 49 +/- 19 microM) and a weak inhibitor of CYP2C9 (Ki > 75 microM), but its effect on the activities of CYP2E1 (Ki = 584 +/- 48 microM) and CYP3A (> 1000 microM) was marginal.	Ticlopidine	0-3	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	37-43	
18474675-2	2008	Mechanism-based CYP2B6 inhibitors (i.e., clopidogrel, ticlopidine, and triethylenethiophoramide) significantly inhibited the formation of M1 from sibutramine and M2 from M1, respectively; in contrast, no effect was observed when using potent inhibitors of eight P450 isozymes (CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A).	Ticlopidine	54-65	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	277-283	
14563790-5	2004	Clopidogrel also inhibited CYP2C9, and ticlopidine also inhibited CYP1A2, with lower potency.	Ticlopidine	39-50	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	66-72